EP0921820A4 - Genterapie für die fettleibigkeit - Google Patents

Genterapie für die fettleibigkeit

Info

Publication number
EP0921820A4
EP0921820A4 EP97932580A EP97932580A EP0921820A4 EP 0921820 A4 EP0921820 A4 EP 0921820A4 EP 97932580 A EP97932580 A EP 97932580A EP 97932580 A EP97932580 A EP 97932580A EP 0921820 A4 EP0921820 A4 EP 0921820A4
Authority
EP
European Patent Office
Prior art keywords
obesity
gene therapy
gene
protein
delivered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97932580A
Other languages
English (en)
French (fr)
Other versions
EP0921820A1 (de
Inventor
Manal A Morsy
Ming Cheng Gu
Jing Zhao
C Thomas Caskey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9615787.0A external-priority patent/GB9615787D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0921820A1 publication Critical patent/EP0921820A1/de
Publication of EP0921820A4 publication Critical patent/EP0921820A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP97932580A 1996-06-20 1997-06-20 Genterapie für die fettleibigkeit Withdrawn EP0921820A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2081296P 1996-06-20 1996-06-20
US20812P 1996-06-20
GB9615787 1996-07-26
GBGB9615787.0A GB9615787D0 (en) 1996-07-26 1996-07-26 Gene therapy for obesity
PCT/US1997/012131 WO1997048419A1 (en) 1996-06-20 1997-06-20 Gene therapy for obesity

Publications (2)

Publication Number Publication Date
EP0921820A1 EP0921820A1 (de) 1999-06-16
EP0921820A4 true EP0921820A4 (de) 2003-01-15

Family

ID=26309766

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97932580A Withdrawn EP0921820A4 (de) 1996-06-20 1997-06-20 Genterapie für die fettleibigkeit

Country Status (4)

Country Link
EP (1) EP0921820A4 (de)
JP (1) JP2000514422A (de)
CA (1) CA2258504A1 (de)
WO (1) WO1997048419A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
CA2335107C (en) * 1998-07-28 2010-01-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Leptin-mediated gene-induction
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US8227408B2 (en) 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
KR20110028457A (ko) 2008-05-21 2011-03-18 뉴로테즈 인코포레이티드 신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법
CA2742600A1 (en) 2008-11-04 2010-05-14 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
PT3074033T (pt) * 2013-11-26 2019-02-08 Childrens Medical Ct Corp Compostos para o tratamento de obesidade e métodos de utilização dos mesmos

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005309A2 (en) * 1994-08-17 1996-02-22 The Rockefeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO1997025424A1 (en) * 1996-01-04 1997-07-17 Amgen Inc. Ob protein receptor and related compositions and methods
WO1997048806A1 (en) * 1996-06-20 1997-12-24 Merck & Co., Inc. Gene therapy for obesity
WO1997049827A2 (en) * 1996-06-26 1997-12-31 Cornell Research Foundation, Inc. Adenoviral mediated gene transfer in adipocytes and related implants

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0826045A1 (de) * 1995-05-08 1998-03-04 Chiron Corporation Nukleinsäuren zur behandlung von feltsucht
US6482927B1 (en) * 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005309A2 (en) * 1994-08-17 1996-02-22 The Rockefeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO1997025424A1 (en) * 1996-01-04 1997-07-17 Amgen Inc. Ob protein receptor and related compositions and methods
WO1997048806A1 (en) * 1996-06-20 1997-12-24 Merck & Co., Inc. Gene therapy for obesity
WO1997049827A2 (en) * 1996-06-26 1997-12-31 Cornell Research Foundation, Inc. Adenoviral mediated gene transfer in adipocytes and related implants

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHUA S C ET AL: "PHENOTYPES OF MOUSE DIABETES AND RAT FATTY DUE TO MUTATIONS IN THE OB (LEPTIN) RECEPTOR", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 271, 16 February 1996 (1996-02-16), pages 994 - 996, XP000941868, ISSN: 0036-8075 *
FLETCHER F A ET AL: "REPLACEMENT GENE THERAPY PHENOTYPICALLY CORRECTS THE FAT DEPOSITIONDEFECT IN OB/OB MICE, RESULTING IN NORMALIZED BODY WEIGHT", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 86, no. 10, SUPPL 1, 15 November 1995 (1995-11-15), pages 241A, XP002042614, ISSN: 0006-4971 *
See also references of WO9748419A1 *

Also Published As

Publication number Publication date
WO1997048419A1 (en) 1997-12-24
JP2000514422A (ja) 2000-10-31
EP0921820A1 (de) 1999-06-16
CA2258504A1 (en) 1997-12-24

Similar Documents

Publication Publication Date Title
AU697311B2 (en) Combined preparation for the therapy of immunological diseases
MY132189A (en) Recombinant obese (ob) proteins
WO1998026747A3 (en) Superantigen based methods and compositions for treatment of diseases
PT923293E (pt) Tratamento da diarreia
WO1998011206A3 (en) THERAPY FOR α-GALACTOSIDASE A DEFICIENCY
DE69733943D1 (de) Verbesserung des sehens durch photodynamische therapie des auges
CA2190011A1 (en) Method for Reduction of Headache Pain
WO1999040197A3 (en) Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
DK0731699T3 (da) Fremgangsmåde til reduktion af legemsfedt i dyr ved indgivelse af konjugeret linolsyre
IT1286236B1 (it) Procedimento per la stimolazione controllata di regioni predefinite del corpo umano tramite l'applicazione di segnali elettrici variabili
EP2295453A3 (de) Appetithemmendes Peptid, Zusammensetzung und Verwendung
EP2295078A3 (de) Verfahren zur Behandlung von Entzündungen
CY1111912T1 (el) Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων
IL130083A0 (en) 3-Pyridyl enantiomers and their use as analgesics
DE59700356D1 (en) Kombinationspräparat, enthaltend 5-methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid und n-(4-trifluormethylphenyl)-2-cyan-3-hydroxycrotonsäureamid
AU3549697A (en) Extracting particles produced by the treating of human or animal nails
ITMI951538A0 (it) Procedimento ed impianto per la disidratazione di foraggio particolarmente per la disidratazione dell'erba medica
CA2230307A1 (en) Aquatic animal treatment method and composition containing cajeput oil
WO2005056601A3 (en) Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse?
CA2221255A1 (en) Use of selegiline to treat hearing loss in mammals
EP0744176A3 (de) Arzneimittel zur Hemmung von Knochenschwund
EP0988316A4 (de) Verfahren und zusammensetzungen für die diagnose und die behandlung von krankheiten, die mit eisenüberschuss oder eisenmangel assoziiert sind.
WO1998037873A3 (en) Method for reducing secretion of apolipoprotein b in animals by administering conjugated linoleic acid
AU1278600A (en) Novel therapeutic application of nicergoline
NZ307139A (en) Method of genetically treating and preventing mastitis and other diseases in animals.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990120

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20021129

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030103